Contraindicated in:
- Active infections
- Hypersensitivity
- Hypersensitivity to other Escherichia coliderived products
- OB: Not recommended for use during pregnancy.
Use Cautiously in:
- Other chronic debilitating illness
- Underlying immunosuppression
- Renal impairment
- Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
- Pedi: Safety and effectiveness not established in children with juvenile rheumatoid arthritis
- Geri: Older adults may be more sensitive to toxicity due to age-related ↓ in renal function; ↑ incidence of infection.
Exercise Extreme Caution in:
- Concurrent use of TNF blocking agents such as etanercept (higher risk of serious infections).
GI: diarrhea, nausea.
Hemat: neutropenia.
Local: injection site reactions.
Neuro: headache.
Misc: hypersensitivity reactions (↑ risk in patients with DIRA), INFECTIONS.
Rheumatoid Arthritis
Neonatal-Onset Multisystem Inflammatory Disease
- SC (Adults and Children): 12 mg/kg/day given in 12 divided doses; may ↑ by 0.51 mg/kg/day, as needed (maximum = 8 mg/kg/day).
Deficiency of Interleukin-1 Receptor Antagonist
- SC (Children): 12 mg/kg/day; may ↑ by 0.51 mg/kg/day, as needed (maximum = 8 mg/kg/day).
Therapeutic Classification: antirheumatics (DMARD)
Pharmacologic Classification: interleukin antagonists
Absorption: Well absorbed (95%) following SUBQ administration.
Distribution: Unknown.
Metabolism/Excretion: Unknown.
Half-life: 46 hr.